RxDoctor Payments Data

Chandler Patton, MD

Pulmonary Disease · Eatontown, NJNPI 1285604868

Payments from drug & device makers

$4,249in general payments, 2019–2025

Across 143 payments — averaging $29.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pulmonx Corporation$731
  • Actelion Pharmaceuticals US, Inc.$618
  • GSK$488
  • AstraZeneca$341
  • Johnson & Johnson$312
  • Boehringer Ingelheim$222
  • plus $2K from 20 others

What the payments were for

  • Travel & lodging$60814%
  • Food & beverage$3,64186%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,249 in reported general payments places this provider in the 60th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$129,985
Medicare patients
287
Services billed
1,362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter154$177,119
Breo ElliptaFluticasone/Vilanterol74$50,914
Spiriva RespimatTiotropium Bromide30$34,991
Incruse ElliptaUmeclidinium Bromide31$27,758
Spiriva HandihalerTiotropium Bromide27$27,075
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$23,489
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$11,935
Tiotropium Bromide11$11,142
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$9,137
Albuterol Sulfate HfaAlbuterol Sulfate168$7,934
Montelukast Sodium309$4,844
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$3,888
Ventolin HfaAlbuterol Sulfate35$3,177
BreynaBudesonide/Formoterol Fumarate15$2,672
Zafirlukast17$2,074

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta$488$279,280280 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$222$46,92646 claims
AstraZenecaBreztri Aerosphere$341$9,13711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Eatontown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →